2-Oxazolidinone, 5,5-dimethyl- → 3-{5-[4-(5-Cyano-3-methylpyridin-2-yl)piperazine-1-carbonyl]pyridin-2-yl}-5,5-dimethyloxazolidin-2-one
반응식
Br[C:2]1[N:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][N:13]([C:16]3[C:23]([CH3:24])=[CH:22][C:19]([C:20]#[N:21])=[CH:18][N:17]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[CH3:25][C:26]1([CH3:32])[O:30][C:29](=[O:31])[NH:28][CH2:27]1>>[C:20]([C:19]1[CH:22]=[C:23]([CH3:24])[C:16]([N:13]2[CH2:14][CH2:15][N:10]([C:8]([C:5]3[CH:4]=[CH:3][C:2]([N:28]4[CH2:27][C:26]([CH3:32])([CH3:25])[O:30][C:29]4=[O:31])=[N:7][CH:6]=3)=[O:9])[CH2:11][CH2:12]2)=[N:17][CH:18]=1)#[N:21]참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Example 1 and using 6-[4-(6-bromopyridine-3-carbonyl)piperazin-1-yl]-5-methylnicotinonitrile (105 mg) described in Preparation Example 131 and 5,5-dimethyloxazolidin-2-one (47 mg) described in Preparation Example 43, the title compound (59 mg) was obtained.
후처리
- customBy reaction and treatment in the same manner as in Example 1